首页>
外国专利>
Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
展开▼
机译:用胶束化形式的大麻素混合物以较低的促炎细胞因子和降低细胞因子风险的风险来治疗Covid 19
展开▼
页面导航
摘要
著录项
相似文献
摘要
This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health.
展开▼